Mycoplasma species detected in 46.9% of cats with respiratory signs in seven-year Czech study

The retrospective case series ran from 2018 to 2025 and found co-detection in 44.9% of cats tested with the same five-pathogen panel.

Mycoplasma species detected in 46.9% of cats with respiratory signs in seven-year Czech study

Photo: Emma Li · Unsplash

A retrospective study of 285 client-owned cats presented with conjunctivitis or respiratory signs between 2018 and 2025 found Mycoplasma species in 46.9%, Filobacterium felis in 42.8% of tested cats, and Ureaplasma species in 38.9%, while FHV-1 was detected in 8.6%, Chlamydia species in 4.3%, and Bordetella bronchiseptica in 1.2%. FCV was not detected. The study was conducted at a veterinary clinic in Prague and used molecular diagnostics to investigate pathogen detection patterns, clinical presentation, and treatment outcomes.

What the study found

Mycoplasma spp. Filobacterium felis, and Ureaplasma spp. were the most frequently detected organisms in cats with respiratory signs, substantially outpacing the traditional viral pathogens FHV-1 and FCV. The study reported that "among 138 cats tested using the same five-pathogen panel, 44.9% were positive for two or more organisms, although no specific pathogen pair showed a statistically significant association." The authors found that clinical presentation (sneezing/rhinitis, conjunctivitis, or cough/pneumonia) "could not be associated with a particular microorganism," with one exception: Chlamydia spp. detection was strongly associated with conjunctivitis (p < 0.001). Follow-up data documented negative post-treatment PCR results for Mycoplasma spp. Ureaplasma spp. and F. felis, but the retrospective design and incomplete follow-up limited comparison of antimicrobial efficacy.

How the study was built

This was a retrospective case series of 285 client-owned cats presented to a single veterinary clinic in Prague, Czechia, between 2018 and 2025. Cats were included if they presented with conjunctivitis and/or respiratory signs. Molecular diagnostics (PCR) were used to detect respiratory pathogens. The study population was not shelter cats; these were client-owned animals in a primary-care setting. A retrospective observational design like this one can identify associations and detection patterns but cannot establish causality or prove that a detected organism is responsible for the clinical signs. The authors state that PCR detection of an organism does not by itself establish a causal role, particularly because several organisms included in respiratory panels may also be detected in clinically healthy cats.

The number, and its error bars

Mycoplasma spp. were detected in 46.9% of the 285 cats. Filobacterium felis was detected in 42.8% of tested cats (the denominator for F. felis testing was not the full 285, as not all cats were tested for all pathogens). Ureaplasma spp. were detected in 38.9% of tested cats. FHV-1 was detected in 8.6%, Chlamydia spp. in 4.3%, and Bordetella bronchiseptica in 1.2%. Among the 138 cats tested using the same five-pathogen panel, 44.9% were positive for two or more organisms. The association between Chlamydia spp. detection and conjunctivitis was statistically significant (p < 0.001). The source does not provide confidence intervals, sensitivity, specificity, or other measures of diagnostic accuracy for the PCR assays used.

What the authors say it cannot tell you

The authors state that detection of a respiratory microorganism by PCR does not necessarily establish its causal role, because several organisms included in respiratory panels may also be detected in clinically healthy cats. This is particularly relevant for Mycoplasma spp. in the upper respiratory tract, where these organisms may be recovered from clinically asymptomatic cats and may form part of the resident microbiota. The authors emphasize that molecular findings should be interpreted in conjunction with the clinical presentation and other diagnostic findings. The retrospective design and incomplete follow-up limited comparison of antimicrobial efficacy. The source does not state other specific limitations of the study design, sample size, or generalizability.

Who paid for it

The source does not state who funded the study or what conflicts of interest were declared.

What this means for your practice

VeterinaryPracticeNow's read, not the study's. Everything in this section is our editorial interpretation for practice owners. The study does not claim any of it.

The detection hierarchy this study found does not match the textbook ordering most of us learned. Detection does not equal causation, and these organisms can be present in healthy cats. That means a positive PCR for Mycoplasma or Ureaplasma in a cat with mild rhinitis does not by itself tell you whether the organism is contributing to the signs, particularly when nearly half the tested cats had multiple organisms detected and no pathogen pair showed a significant association.

The clinical question is whether molecular diagnostics change your antimicrobial decision often enough to justify the cost. The study notes that organisms associated with similar clinical presentations may require different antimicrobial approaches, particularly F. felis. Detected in a substantial proportion of tested cats in this series, it is an emerging pathogen that may not respond to the same empirical protocols used for Mycoplasma or Chlamydia. The Chlamydia-conjunctivitis association is the one finding in this study that does predict pathogen from presentation, and it is the one that matches what we already do clinically.

We write one of these every week for people who practice this stuff. subscribe to VeterinaryPracticeNow.

The business question for owner-DVMs is whether in-house or send-out respiratory panels justify their cost versus presumptive protocols in the average URI case. This study does not answer that. It shows what gets detected, not what percentage of cases resolve without testing. The cost justification depends on your case mix, your empirical success rate, and whether the panel result changes the drug you dispense often enough to pay for itself. We're hearing more practices run the panel on second presentations or when the first protocol fails, rather than on every snotty nose that walks in, and this detection pattern supports that approach.

Get the next issue in your inbox. Free, weekly, no fluff.

Unsubscribe anytime.

Source: Frontiers in Veterinary Science ↗

← Back to the Newsdesk